<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364916">
  <stage>Registered</stage>
  <submitdate>6/09/2013</submitdate>
  <approvaldate>10/09/2013</approvaldate>
  <actrnumber>ACTRN12613000999730</actrnumber>
  <trial_identification>
    <studytitle>Sodium control in aneurysmal subarachnoid haemorrhage</studytitle>
    <scientifictitle>The effect of fludrocortisone plus standard care on sodium control in aneurysmal subarachnoid haemorrhage</scientifictitle>
    <utrn>U1111-1147-6570</utrn>
    <trialacronym>Sodium control in SAH</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyponatraemia in subarachnoid haemorrhage</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Fludrocortisone 100mcg oral tablet twice daily in addition to standard care until hyponatremia resolves per twice daily serum electrolytes
Adherence ensured by tablets being administered by nursing staff on hospital ward</interventions>
    <comparator>Comparator is standard medical care: 
intravenous fluid, and possibly oral fluid restriction and/or intravenous hypertonic saline
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sodium nadir by twice daily serum electrolytes</outcome>
      <timepoint>Day 1-18 post aneurysmal subarachnoid haemorrhage</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration sodium &lt;135mmol/L according to twice daily serum electrolytes</outcome>
      <timepoint>Day 1-18 post subarachnoid haemorrhage</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration and intensity of oral fluid restriction, according to mL oral fluid consumed daily</outcome>
      <timepoint>Day 1-18 post aneurysmal subarachnoid haemorrhage</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration and intensity of hypertonic saline delivery, according to mL hypertonic saline delivered daily</outcome>
      <timepoint>Day 1-18 post subarachnoid haemorrhage</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion: 
*	D1-18 aneurysmal SAH
*	Serum Na &lt;135mmol/L
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion: 
*	Thyroid abnormality
*	Cortisol abnormality
*	Pre-morbid cardiopulmonary disease
*	Pre-morbid electrolyte imbalance
*	Pre-morbid treated hypertension
*	Pre-morbid systemic fungal infection
*	Women who are pregnant 
*	Children and/or young people (&lt;18 years)
*	Aged (&gt;80 years)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/10/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode>4102 - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Stephanie Teasdale</primarysponsorname>
    <primarysponsoraddress>Department of Diabetes and Endocrinology, Princess Alexandra Hospital
25 Manson Pde
Yeronga
Qld 4104
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Unfunded</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hyponatremia, which describes low blood sodium levels, occurs frequently in patients who are in the hospital after aneurysmal subarachnoid haemorrhage, a condition where there has been bleeding in the brain. Hyponatremia can cause confusion and seizures, and possibly long term effects on a patients ability to function. A substantial amount of resources are used in treating this condition.  
This study looks at determining whether a medication called fludrocortisone can help in reducing the severity and duration of hyponatremia in this setting.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metro South Human Research Ethics Committee (EC00167) </ethicname>
      <ethicaddress>Centres for Health Research
Level 7 TRI
37 Kent Street WOOLLOONGABBA QLD 4102</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>19/09/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Stephanie Teasdale</name>
      <address>Endocrine registrar, Department of Diabetes and Endocrinology at PA Hospital
25 Manson Pde
Yeronga
Qld 4104</address>
      <phone>+61438336950</phone>
      <fax />
      <email>stephanie_teasdale@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephanie Teasdale</name>
      <address>Dept of Diabetes and Endocrinology
Princess Alexandra Hospital
Ipswich Rd
Woolloongabba
Qld 4102</address>
      <phone>+61731762111</phone>
      <fax />
      <email>stephanie_teasdale@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephanie Teasdale</name>
      <address>Department of Diabetes and Endocrinology, PA Hospital
25 Manson Pde
Yeronga
Qld 
4104</address>
      <phone>+61438336950</phone>
      <fax />
      <email>stephanie_teasdale@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>stephanie Teasdale</name>
      <address>25 Manson Pde
Yeronga
Qld
4104</address>
      <phone>+61438336950</phone>
      <fax />
      <email>stephanie_teasdale@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>